SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience

SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience

BackgroundPreventive strategies against severe COVID-19 in Inborn Errors of Immunity (IEI) include bivalent vaccines, treatment with SARS-CoV-2 monoclonal antibodies (mAbs), early antiviral therapies, and pre-exposure prophylaxis (PrEP).ObjectiveTo assess the effectiveness of the PrEP with tixagevim...

Full description

Bibliographic Details
Main Authors: Federica Pulvirenti, Giulia Garzi, Cinzia Milito, Eleonora Sculco, Maddalena Sciannamea, Anna Napoli, Lilia Cinti, Piergiorgio Roberto, Alessandra Punziano, Maria Carrabba, Eva Piano Mortari, Rita Carsetti, Guido Antonelli, Isabella Quinti
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID-19
inborn errors of immunity
immunoglobulin replacement (IgRT)
monoclonal antibody
tixagevimab/cilgavimab prophylaxis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249462/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249462/full

Similar Items